Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT00658749 Completed - Asthma Clinical Trials

A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma

AIR645-CS1
Start date: April 2008
Phase: Phase 1
Study type: Interventional

This is a phase one study to evaluate the safety, tolerability, and bioavailability of nebulized AIR645.

NCT ID: NCT00657891 Completed - Asthma Clinical Trials

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

Start date: March 2007
Phase: Phase 4
Study type: Interventional

We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.

NCT ID: NCT00657774 Completed - Asthma Clinical Trials

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiFormâ„¢ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of the two medications in one inhaler. The purpose of the study is to determine how the medication affects the amount, if any, of cortisol produced by the adrenal glands.

NCT ID: NCT00655616 Completed - Asthma Clinical Trials

Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics

Start date: August 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether patients with asthma who carry a genotype associated with adverse outcomes with long-acting beta-2 agonists like salmeterol show greater benefit from the use of an asthma drug that works via alternative pathways like montelukast.

NCT ID: NCT00652392 Completed - Asthma Clinical Trials

Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM

Start date: April 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare a dose of Symbicort taken once daily with other dosage regimens of Symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults

NCT ID: NCT00652223 Completed - Allergic Asthma Clinical Trials

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

NCT ID: NCT00652002 Completed - Asthma Clinical Trials

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults

NCT ID: NCT00651768 Completed - Asthma Clinical Trials

Titratable Dosing in Moderate to Severe Asthmatics

Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the long term safety of Symbicort with budesonide alone, in adolescents and adults with asthma.

NCT ID: NCT00651651 Completed - Asthma Clinical Trials

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Symbicort with its monocomponents budesonide and formoterol in the treatment of asthma in children and adults

NCT ID: NCT00651547 Completed - Asthma Clinical Trials

Symbicort in Asthmatic Children - SEEDLING

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare Symbicort with budesonide alone and formoterol alone in the treatment of asthma in children aged 6 to 11 years